<DOC>
	<DOC>NCT01133405</DOC>
	<brief_summary>This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 single doses, how the body handles the drug, and the drug's effect on the body.</brief_summary>
	<brief_title>A Safety Study of LY2886721 Single Doses in Healthy Subjects</brief_title>
	<detailed_description>This is a Phase 1 study with 2 parts, both in healthy subjects. Part 1 is a subject- and investigator-blind, placebo-controlled, randomized, 3-period, crossover study. Part 1 will assess the safety and tolerability of LY2886721 single doses, how the body handles the drug, and the drug's effect on the body. Part 2 is a subject- and investigator-blind, placebo-controlled, randomized study to assess the safety and tolerability of an LY2886721 single dose, how the body handles the drug, and the drug's effect on the body including in cerebrospinal fluid.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy men and nonchildbearing potential women 20 years or older Body mass index between 1832 kg/m2 Taking overthecounter or prescription medication with the exception of vitamins or minerals or stable doses of thyroid or estrogen hormone replacement Smoke more than 10 cigarettes per day</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>